ZACHARY ANDOR: Open Payments
NPI 1992405344 · GENEVA, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,797 in 122 payments from 34 companies in 2025. Trend: 2023 $3,281 · 2024 $3,181 · 2025 $2,797
Food & beverage: $2,797
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 27 | $400 |
| ABBVIE INC. | 17 | $329 |
| Merck Sharp & Dohme LLC | 8 | $191 |
| Janssen Biotech, Inc. | 6 | $139 |
| Tempus AI, Inc | 1 | $134 |
| AstraZeneca Pharmaceuticals LP | 4 | $129 |
| Astellas Pharma US Inc | 4 | $126 |
| GlaxoSmithKline, LLC. | 6 | $122 |
| Agios Pharmaceuticals, Inc. | 4 | $121 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $113 |
Products named: KEYTRUDA, Venclexta, KISQALI, XT CDX, LYNPARZA, PYRUKYND, Vyloy, RYBREVANT.
Industry payments across IL — which companies pay providers there.
